SCHEDULE: Armistice Capital Amends Enlivex Stake to 4.99%

Armistice Capital and Steven Boyd have filed an amendment to their Schedule 13G, disclosing a 4.99% beneficial ownership in Enlivex Therapeutics Ltd.'s Ordinary Shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,178,389 Ordinary Shares of Enlivex Therapeutics Ltd.
• This represents 4.99% of the issuer's class of securities.
• The filing is an Amendment No. 3 to a previously filed Schedule 13G.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both reporting persons share voting and dispositive power over all 1,178,389 shares.
• The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.

Positives

• The filing indicates continued investment by Armistice Capital and Steven Boyd in Enlivex Therapeutics Ltd., suggesting ongoing confidence in the company by these investors.

Negatives

• No specific negative information is contained within this beneficial ownership report.

Risks

• This filing is a disclosure of beneficial ownership and does not contain information regarding company-specific operational or financial risks.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not provide forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

Schedule 13G filings are routine disclosures by passive investors who own more than 5% of a company's stock, or who previously crossed that threshold and are updating their holdings. This amendment indicates a continued, passive investment by Armistice Capital and Steven Boyd in Enlivex Therapeutics, a biotechnology company. The 4.99% stake is just below the 5% threshold that would typically trigger a Schedule 13D filing, which implies an intent to influence or control the company.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for beneficial ownership and does not contain performance metrics for comparison to industry standards.
• The reported ownership percentage of 4.99% is a significant institutional stake, though it remains below the 5% threshold that would necessitate a Schedule 13D filing, which is typically associated with more active investor intent or potential corporate governance influence.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming Armistice Capital and Steven Boyd's continued passive stake in the company.

Key Dates

Keywords

Enlivex Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Investment Adviser, Biotechnology Investment